ArticleCell2018
Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production.
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
171 citing papers in PubMed.
- Proteomics of heterogeneous megakaryocytes identifies JI051 as an enhancer of platelet biogenesis.Life science alliance · 2026Article
- Scalable generation of T lymphocytes from human pluripotent stem cells in suspended organoids.Stem cell reports · 2026Article
- Thyroid hormones induce an acute platelet release mechanism via integrin αVβ3.Haematologica · 2026Article
- The KXD1-TSPAN14 axis controls megakaryopoiesis and platelet production via Notch signaling.Science China. Life sciences · 2026Article
- First evidence of the circulation of induced pluripotent stem cell-derived platelets in humans.Stem cells translational medicine · 2026Article
- Efficient chemical reprogramming of human T cells into functional megakaryocytes and platelets.Science advances · 2026Article
- Lyophilized Synthetic Platelets: In Vitro Characterization and In Vivo Evaluation in Mouse Thrombocytopenia Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Laboratory Assessment and Clinical Outlook forAnnals of laboratory medicine · 2026Review
- Hematopoietic stem and progenitor cells derived platelet lysate promotes diabetic wound healing.Molecular medicine (Cambridge, Mass.) · 2026Article
- Generation and single-cell characterization of functional megakaryocytes derived from umbilical cord blood.Stem cell research & therapy · 2026Article
- Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026Review
- Redox Regulation of Megakaryocyte Differentiation and Platelet Biogenesis.Antioxidants (Basel, Switzerland) · 2026Review
- Thermo-Chemically Modified Silk Scaffolds Reveal Niche-Driven Regulation of Hematopoiesis and Fibrosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Plasma Proteomic Profile of Chemotherapy-Induced Severe Neutropenia: A Pilot Discovery Phase Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Induced pluripotent stem cell-derived platelets kill multidrug-resistantResearch and practice in thrombosis and haemostasis · 2026Article
- Give megs a break: minor DNA stress, platelets in excess.Blood advances · 2026Article
- Hematopoietic organoids: Opportunities and challenges in modeling human hematopoiesis and diseases in vitro.Stem cell reports · 2026Review
- Blood Mechanical Intelligence: From Force Sensing to Precision Mechanomedicine.Research (Washington, D.C.) · 2026Review
- Aging-dependent reduction of KAT7/HBO1 activity impairs imMKCL-based platelet production by promoting immune properties.Stem cell reports · 2025Article
111 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ex vivo generation of platelets from human-induced pluripotent cells (hiPSCs) is expected to compensate donor-dependent transfusion systems. However, manufacturing the clinically required number of platelets remains unachieved due to the low platelet release from hiPSC-derived megakaryocytes (hiPSC-MKs). Here, we report turbulence as a physical regulator in thrombopoiesis in vivo and its application to turbulence-controllable bioreactors. The identification of turbulent energy as a determinant parameter allowed scale-up to 8 L for the generation of 100 billion-order platelets from hiPSC-MKs, which satisfies clinical requirements. Turbulent flow promoted the release from megakaryocytes of IGFBP2, MIF, and Nardilysin to facilitate platelet shedding. hiPSC-platelets showed properties of bona fide human platelets, including circulation and hemostasis capacities upon transfusion in two animal models. This study provides a concept in which a coordinated physico-chemical mechanism promotes platelet biogenesis and an innovative strategy for ex vivo platelet manufacturing.
Indexed as
Identifiers
30017246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.